Sparsentan

TargetMol
Product Code: TAR-T5355
Supplier: TargetMol
CodeSizePrice
TAR-T5355-1mg1mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5355-2mg2mg£133.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5355-5mg5mg£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5355-1mL1 mL * 10 mM (in DMSO)£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5355-10mg10mg£217.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5355-25mg25mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5355-50mg50mg£437.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5355-100mg100mg£608.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5355-500mg500mg£1,211.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Sparsentan is a first-in-class orally active and highly potent dual endothelin A and angiotensin II receptor antagonist(Ki of 9.3 and 0.8 nM, respectively)
CAS:
254740-64-2
Formula:
C32H40N4O5S
Molecular Weight:
592.76
Pathway:
Endocrinology/Hormones; GPCR/G Protein
Purity:
0.9881
SMILES:
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(c(COCC)c1)-c1ccccc1S(=O)(=O)Nc1noc(C)c1C
Target:
RAAS; Endothelin Receptor

References

Komers R , Diva U , Inrig J K , et al. Study Design of the Phase 3 Sparsentan vs Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis (FSGS)[J]. Kidney International Reports, 2020, 5(4). Komers R , Gipson D S , Nelson P , et al. Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)[J]. Kidney International Reports, 2017:654-664. Murugesan N, et al. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem. 2005 Jan 13;48(1):171-9.